drugset
drugset / Trial / NCT07236411

Absolute Bioavailability Study of Cizutamig in Healthy Adult Participants

NCT07236411 ↗

Phase 1 Active not recruiting 24 enrolled Candid Therapeutics
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine the absolute bioavailability of SC administered cizutamig in healthy adult participants.

Timeline

Start
2025-12-04
Primary completion
2026-06
Completion
2026-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Cizutamig Protein / enzyme biologic — Subcutaneous

Indications

No indication recorded.